title: A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation.
abstract: Lung adenocarcinoma includes recurrent activating oncogenic mutations (EGFR, EML4-ALK, ROS1) that have been associated with response to EGFR and ALK inhibitors. Platinum-based chemotherapy is the standard therapy for non-oncodrivers population. Sorafenib is a small molecule that blocks the activation of C-RAF, B-RAF, c-KIT, FLT-3, RET, VEGFR-2, VEGFR-3 and PDGFR approved for advanced renal cell and hepatocellular carcinoma (b, c). Many studies have evaluated sorafenib in advanced non-small-cell lung cancer (NSCLC), with different results. We present a case report of a patient with NSCLC and the BRAF G469R mutation who showed a dramatic response to sorafenib.
authors.affiliation: aMedical Oncology Department bPrecision Oncology Laboratory (POL) cPathology Department, Infanta Sofía University Hospital dIMDEA-Food Institute, CEI UAM+CSIC eClinical Research Phase 1 Trials Unit, START Madrid-FJD, Hospital Fundación Jiménez Díaz Fundación Jiménez Díaz, Madrid, Spain.
authors.forename: María
authors.initials: M
authors.lastname: Sereno
authors.forename: Victor
authors.initials: V
authors.lastname: Moreno
authors.forename: Juan
authors.initials: J
authors.lastname: Moreno Rubio
authors.forename: César
authors.initials: C
authors.lastname: Gómez-Raposo
authors.forename: Sagrario
authors.initials: S
authors.lastname: García Sánchez
authors.forename: Rebeca
authors.initials: R
authors.lastname: Hernández Jusdado
authors.forename: Sandra
authors.initials: S
authors.lastname: Falagan
authors.forename: Francisco
authors.initials: F
authors.lastname: Zambrana Tébar
authors.forename: Enrique
authors.initials: E
authors.lastname: Casado Sáenz
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000235:genetics; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D008875:Middle Aged; D009154:Mutation; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf